LONDON: Open Orphan plc is at an advanced stage in planning for a possible spin-out of certain non-core Development IP Assets. These Development IP Assets are a portfoilio of intellectual property and development assets, including HVO-001 which has potential application in the treatment of respiratory disease. These do not include the equity interests in Imutex…
All posts tagged Open Orphan plc
Open Orphan launches Covid-19 antibody testing service
LONDON: Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, announced the launch of hVIVO COVID Clear Test, the Company’s antibody testing service, following the successful completion of installation, testing and training. The antibody tests,…